The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
2014 Opportunities in the UK Drugs of Abuse Testing Market
US$ 1,960.00
... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...
December 2013
260 pages
2014 Opportunities in the US Drugs of Abuse Testing Market
US$ 2,800.00
... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...
December 2013
262 pages
2014 Opportunities in the European Drugs of Abuse Testing Market
US$ 5,200.00
This new 300-page report from Venture Planning Group provides a comprehensive analysis of the European drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...
December 2013
300 pages
Research Report on China Antidiabetic Drug Market, 2014-2018
US$ 2,400.00
... and cure to diabetes become more difficult. The prevalence rate of diabetes in China increased from less 1% in 1980 to about 5.5% in 2022, 11% in 2013, which become the ... . The CAGR in 2009-2013 exceeded 17%. CRI estimates the CAGR of China antidiabetic drug market size will keep 15%. For global pharmaceutical ...
December 2013
60 pages
Market Access for Orphan Drugs: assessing the global landscape
US$ 595.00
... high cost of orphan drugs. International and regional regulations are also hurdles to be overcome, despite harmonisations efforts by agencies. In Market Access for Orphan Drugs: Assessing the Global Landscape, FirstWord goes around the world to lay bare the market access issues affecting orphan drug developers in the ...
December 2013
100 pages
2014 Nucleic Acid Testing Market: Strategic Assessments of Leading Strategic Suppliers
US$ 2,800.00
This 549-page report presents an overview of the clinical significance and market needs for major current and emerging NAT assays, as well as ... assessments of current and emerging suppliers of nucleic acid testing products, including their sales, product portfolios, marketing tactics, technological know-how, ...
November 2013
549 pages
Research Report on China Osteoporosis Drug Market, 2013-2017
US$ 1,800.00
... vitamin D and analogues, and calcitonins always took up above 98% shares of China osteoporosis drug market. The market share of bisphosphonates increased at the ... global pharmaceutical enterprises, they will find huge market opportunities in China. Through this report, the readers can acquire the following ...
November 2013
30 pages
2014 Analysis of the Global Drugs of Abuse Testing Market: US, Europe (France, Germany, Italy, Spain, UK), Japan
US$ 6,800.00
... (test volumes, sales forecasts, supplier shares) $5,500. This new 318-page report from Venture Planning Group contains 68 tables and provides analysis of the global drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic ...
November 2013
318 pages
2014 Analysis of the UK Drugs of Abuse Testing Market: Hospitals and Commercial Labs
US$ 1,960.00
This new 260-page report from Venture Planning Group provides a comprehensive analysis of the UK drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...
November 2013
260 pages
2014 Analysis of the European Drugs of Abuse Testing Market: Hospitals, Commercial Labs, Physician Offices, Ambulatory Care Centers
US$ 5,200.00
This new 300-page report from Venture Planning Group provides a comprehensive analysis of the European drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...
November 2013
300 pages
2014 Analysis of the Global Therapeutic Drug Monitoring (TDM) Market: US, Europe (France, Germany, Italy, Spain, UK), Japan
US$ 6,800.00
... volumes, sales forecasts, supplier shares) $5,500. This new 313-page report from Venture Planning Group contains 83 tables and provides analysis of the global therapeutic drug monitoring testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and ...
November 2013
313 pages
2014 Analysis of the European Therapeutic Drug Monitoring (TDM) Market : Hospitals, Commercial Labs, Physician Offices, Ambulatory Care Centers
US$ 5,200.00
This new 291-page report from Venture Planning Group provides a comprehensive analysis of the European therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and ...
November 2013
291 pages
US Lung Cancer Drug Pipeline Analysis
US$ 1,800.00
... annual statistics published, an estimated 201,144 people in the United States were diagnosed with lung cancer. This figure included 107,164 men and ... drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Lung Cancer Drug Pipeline Analysis ...
November 2013
385 pages
US Colorectal Cancer Drug Pipeline Analysis
US$ 1,500.00
... that the US would witness a modest increase in the prevalence of the disease, mostly as a result of the country having already reached epidemic proportions ... market based upon development process. Following parameters for each drug profile in development phase are covered in “US Colorectal Cancer Drug Pipeline ...
November 2013
242 pages
US Parkinson's Disease Drug Pipeline Analysis
US$ 1,500.00
... in the near future. It has been estimated that at least 500,000 people in the United States currently have been diagnosed with this disease. ... drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Parkinson’s Disease Drug Pipeline Analysis ...
November 2013
241 pages
Global RNAi Drug Pipeline Analysis
US$ 1,500.00
... location. “Global RNAi Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed based upon RNAi technology. ... Drug market based upon development process. Following parameters for each drug profile in development phase are covered in “Global RNAi Drug Pipeline ...
October 2013
250 pages
US Orphan Drug Pipeline Analysis
US$ 1,800.00
... from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the ... increasing, thus increasing the profit margins in the future. “US Orphan Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ...
October 2013
880 pages
Global Infertility Drug Pipeline Analysis
US$ 1,000.00
... drugs and treatment. The most lucrative markets for infertility drugs are the emerging nations such as India, Brazil, China and Mexico, ... pool of people being affected by lifestyle diseases, thus leading to infertility. “Global Infertility Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the ...
October 2013
60 pages
Orphan Drugs for Cancer Pipeline Analysis
US$ 1,800.00
... patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group ... drug profile in development phase are covered in “Orphan Drugs for Cancer Pipeline Analysis” research report: Drug Profile Overview Alternate Names for Drug ...
October 2013
855 pages
Global HIV Infection Drug Pipeline Analysis
US$ 1,500.00
... to identify and analyze the available investment opportunity in the HIV Infection drug market based upon development process. Following parameters for each drug profile in clinical development phase are covered in “Global HIV Infection Drug Pipeline Analysis” research report: Drug ...
October 2013
300 pages
US Alzheimer Drug Pipeline Analysis
US$ 2,000.00
... observed that almost 1 in 8 people coming under the 65+ age group are patients of Alzeimer’s disease. Amongst the population in the 80+ age group, almost ... market based upon development process. Following parameters for each drug profile in development phase are covered in “US Alzheimer Drug Pipeline Analysis” ...
October 2013
348 pages
US Prostate Cancer Drug Pipeline Analysis
US$ 1,800.00
... Clinical Trial Owner / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes US Prostate Cancer Drug Pipeline by Clinical Phase: Research: 11 Preclinical: 44 Unknown Phase: 4 Phase 0: 1 Phase-I: 22 Phase-I/II: 18 Phase-II: 53 Phase-II/III: 1 Phase-III:14 Marketed: 13
October 2013
375 pages
US Breast Cancer Drug Pipeline Analysis
US$ 1,800.00
... and new therapies would account for more than 25% of the overall market for breast cancer drug treatments. “US Breast Cancer Drug Pipeline Analysis” by ... drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Breast Cancer Drug Pipeline ...
October 2013
480 pages
Europe Breast Cancer Drug Pipeline Analysis
US$ 1,800.00
... opportunity in the Breast Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “Europe Breast Cancer Drug Pipeline Analysis” research report: Drug Profile Overview Alternate Names ...
October 2013
380 pages
Gene Therapy Drug Pipeline Analysis
US$ 1,500.00
... in development phase enables the reader to identify and understand the Gene Therapy associated with the various diseases. This report enables pharmaceutical ... parameters for each drug profile in development phase are covered in “Gene Therapy Drug Pipeline Analysis” research report: Drug Profile Overview ...
September 2013
185 pages
Malaria Disease Drug Pipeline Analysis
US$ 1,200.00
... purchasing Hard Copy License depending on the location. “Malaria Disease Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ... on the development process. Insight for each drug profile in development phase enables the reader to identify and understand the therapeutics associated ...
August 2013
185 pages
2013 Drugs of Abuse Testing in France: Hospitals and Commercial Labs
US$ 1,960.00
... shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for ... as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in France: Hospitals and Commercial Labs” is a unique study designed ...
June 2013
260 pages
2013 Drugs of Abuse Testing in Germany: Hospitals, Commercial Labs, Physician Offices
US$ 1,960.00
... of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in Germany: Hospitals, Commercial Labs, Physician Offices” is a unique study designed to help current suppliers and potential market entrants ...
June 2013
262 pages
2013 Drugs of Abuse Testing in Italy: Hospitals and Commercial Labs
US$ 1,960.00
... shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for ... as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in Italy: Hospitals and Commercial Labs” is a unique study designed ...
June 2013
260 pages
2013 Drugs of Abuse Testing in Japan: Hospitals and Commercial Labs
US$ 2,200.00
... shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for ... as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in Japan: Hospitals and Commercial Labs” is a unique study designed ...
June 2013
260 pages
2013 Drugs of Abuse Testing in Spain: Hospitals, Commercial Labs, Ambulatory Care Centers
US$ 1,960.00
... of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in Spain: Hospitals, Commercial Labs, Ambulatory Care Centers” is a unique study designed to help current suppliers and potential market entrants ...
June 2013
260 pages
2013 Drugs of Abuse Testing in the UK: Hospitals and Commercial Labs
US$ 1,960.00
... resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace ... , such as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in the UK: Hospitals and Commercial Labs” is a unique study ...
June 2013
260 pages
2013 Drugs of Abuse Testing in the US: Hospitals, Commercial Labs, Physician Offices
US$ 2,800.00
... for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in the US: Hospitals, Commercial Labs, Physician Offices” is a unique study designed to help current suppliers and potential market ...
June 2013
262 pages
2013 Drugs of Abuse Testing in Europe: Hospitals, Commercial Labs, Physician Offices, Ambulatory Care Centers
US$ 5,200.00
... a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in Europe: Hospitals, Commercial Labs, Physician Offices, Ambulatory Care Centers” is a unique study designed to help current suppliers ...
June 2013
300 pages
2013 Therapeutic Drug Monitoring (TDM) Market in Europe: Hospitals, Commercial Labs, Physician Offices, Ambulatory Care Centers
US$ 5,200.00
... Acid and Vancomycin. During the next five years, the TDM market will undergo significant transformation. These changes will be caused ... as specimen preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market in the US: Hospitals, Commercial Labs, Physician Offices, ...
June 2013
291 pages
2013 Therapeutic Drug Monitoring (TDM) Market in France: Hospitals and Commercial Labs
US$ 1,960.00
... preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market in France: Hospitals and Commercial Labs” is a unique market and ... responses. The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors. ...
June 2013
247 pages
